- $13.77m
- $3.64m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.95 | ||
| Price to Tang. Book | 0.95 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -171.7% | ||
| Return on Equity | -154.44% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Directors
- Alan Roemer CHM (42)
- William Ho PRE (45)
- Lawrence Lamb CFD (67)
- Patrick Mccall CFO (38)
- Kate Rochlin COO (40)
- Melissa Beelen VOP (54)
- Trishna Goswami OTH
- Peter Brandt DRC (64)
- Thomas Cirrito DRC (48)
- Travis Whitfill DRC (31)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 7th, 2018
- Public Since
- November 12th, 2020
- No. of Shareholders
- 41
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 81,258,763
- Address
- Empire State Building, NEW YORK, 10118
- Web
- https://www.in8bio.com
- Phone
- +1 6466006438
- Auditors
- CohnReznick LLP
Upcoming Events for INAB
IN8bio Inc Annual Shareholders Meeting
Similar to INAB
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the IN8bio share price?
As of Today at 21:16 UTC, shares in IN8bio are trading at $0.17. This share price information is delayed by 15 minutes.
How has the IN8bio share price performed this year?
Shares in IN8bio last closed at $0.17 and the price had moved by -83.38% over the past 365 days. In terms of relative price strength the IN8bio share price has underperformed the S&P500 Index by -85.02% over the past year.
What are the analyst and broker recommendations for IN8bio?
There is no consensus recommendation for this security.
Find out moreWhat is the IN8bio dividend yield?
IN8bio does not currently pay a dividend.
Does IN8bio pay a dividend?
IN8bio does not currently pay a dividend.
When does IN8bio next pay dividends?
IN8bio does not currently pay a dividend.
How do I buy IN8bio shares?
To buy shares in IN8bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IN8bio?
As of the previous close price of $0.17, shares in IN8bio had a market capitalisation of $13.77m.
Where are IN8bio shares listed?
Here are the trading details for IN8bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INAB
What kind of share is IN8bio?
Based on an overall assessment of its quality, value and momentum IN8bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IN8bio share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the IN8bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IN8bio. Over the past six months, its share price has underperformed the S&P500 Index by -40.55%.
As of the last closing price of $0.17, shares in IN8bio were trading -50.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IN8bio PE Ratio?
The IN8bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IN8bio?
IN8bio's management team is headed by:
- Alan Roemer - CHM
- William Ho - PRE
- Lawrence Lamb - CFD
- Patrick Mccall - CFO
- Kate Rochlin - COO
- Melissa Beelen - VOP
- Trishna Goswami - OTH
- Peter Brandt - DRC
- Thomas Cirrito - DRC
- Travis Whitfill - DRC